1. Home
  2. IMMX vs VALN Comparison

IMMX vs VALN Comparison

Compare IMMX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$9.58

Market Cap

528.0M

Sector

Health Care

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$5.58

Market Cap

536.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMX
VALN
Founded
2014
2012
Country
United States
France
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
528.0M
536.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
IMMX
VALN
Price
$9.58
$5.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$19.20
$15.50
AVG Volume (30 Days)
691.0K
77.8K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$93.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.87
$5.06
52 Week High
$11.61
$12.25

Technical Indicators

Market Signals
Indicator
IMMX
VALN
Relative Strength Index (RSI) 52.62 38.10
Support Level $8.15 $5.15
Resistance Level $10.53 $6.42
Average True Range (ATR) 0.73 0.21
MACD -0.00 0.13
Stochastic Oscillator 63.09 43.86

Price Performance

Historical Comparison
IMMX
VALN

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: